Recently, reliable quantification of NfL became possible with the introduction of the Simoa assays in blood and CSF, across the full range of concentrations including in healthy participants.17 Our results suggest that an even more sensitive future technology might be needed to detect NfL in urine since we did find an NfL signal in a few FTD patients. The gene discussed is NEFL; the disease is frontotemporal dementia.